Three Belgian researchers tested the diagnostic value of two serum markers in muscle pathology: the chemokine CXCL10 and the cytokine GDF5.
- These biomarkers were measured in 21 patients with autoimmune necrotising myopathy (ANIM), 18 with sporadic inclusion myositis (SIM), three with overlapping myositis, two with dermatomyositis and one with an anti-synthetase syndrome,
- all were compared with 10 healthy subjects and 14 with hereditary muscle pathology,
- CXCL10 levels were found to be almost 10 times higher in autoimmune processes than in normal subjects,
- defining a detection threshold of 300 pg/mL for the GDF15 assay reduces the number of false negatives in NAMI.
The authors suggest incorporating these two new biomarkers into dot-myositis.
